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Summary
Hypercalciuria may be classified into absorptive, renal and re-
sorptive forms, depending on whether the primary defect is in-
testinal hyperabsorption of calcium, renal leak of calcium, or
excessive bone resorption. In absorptive hypercalciuria, the
pathogenetic role of vitamin D is uncertain, and mutations in
the chloride channel may occur mainly in association with
Dent’s disease. Early studies suggest that a new soluble
adenylyl cyclase (A H R A C) may be etiologically important in
this condition, since base changes in this gene occur much
more frequently and are directly correlated with intestinal cal-
cium absorption. 
The distal nephron is the site of reabsorption of the final 20%
of filtered calcium. The transcellular reabsorption of calcium
begins with a passive entry of Ca2 + through apical calcium
channels, followed by diffusion through cytosol and active ex-
trusion across the basolateral membrane. Calcium transport
in the nephron is regulated by luminal pH, calcitriol, estrogen,
parathyroid hormone, prostaglandin E2, and sodium load. A
biochemical picture of renal hypercalciuria may be produced
by acid load from dietary animal proteins, prostaglandin E2 ex-
cess, sodium load, hypoparathyroidism, and estrogen defi-
ciency. So far, mutations in apical calcium channel have not
been found. 
The hallmark of resorptive hypercalciuria is primary hyper-
parathyroidism. Bone loss often accompanies absorptive hy-
percalciuria. A H R A C may be implicated, since base changes
in this gene are inversely correlated with spinal bone density.
Dietary acid load from high animal protein diet may cause hy-
percalciuria, in part by stimulating bone loss. 
KEY WORDS: primary hypercalciuria, renal calcium excretion, intestinal cal -
cium absorption.
Introduction
Hypercalciuria is clinically important since it often accompanies
the formation of calcium-containing kidney stones. Among pa-
tients with idiopathic calcium oxalate nephrolithiasis, hypercal-
ciuria is the main determinant for the formation of calcium
phosphate nidus (in the thin loops of Henle of the nephron) that
may initiate calcium oxalate crystallization (1). The correction
of hypercalciuria by thiazide or indapamide has been reported
to reduce the rate of recurrent stone formation (2). In a risk
analysis, hypercalciuria confers a higher risk for stone forma-
tion than hyperoxaluria (3). 
The pathophysiologic basis for hypercalciuria is multifactorial,
involving disturbance in calcium handling at three organs - in-
testine, kidneys and bone. Accordingly, hypercalciuria has
been classified into absorptive, renal and resorptive forms, de-
pending on whether the principal defect is intestinal hyperab-
sorption of calcium, “renal leak” of calcium or excessive bone
resorption (4). This article will review recent advances in the
pathophysiology of each of three main causes of hypercalci-
uria. It is understood, however, that a primary defect in calcium
handling in one organ system may produce a secondary distur-
bance in other organ system. Moreover, in some conditions,
calcium handling may be primarily disturbed in more than one
organ systems. 
Pathophysiology of absorptive hypercalciuria (Table I)
Table I - Pathophysiology of Absorptive Hypercalciuria.
1. General Description
2. Potential Pathogenetic Role of Vitamin D
3. Genetic Basis of Absorptive Hypercalciuria
a. AHRAC Gene
b. Chloride Transporter
4. Sarcoidosis
General Description
Absorptive hypercalciuria (AH) describes a stone-forming con-
dition in which the primary defect is presumed to be enhanced
intestinal absorption of calcium (4,5). The increased absorbed
calcium transiently raises serum calcium and suppresses
parathyroid function. Hypercalciuria ensues from the increased
renal filtered load of calcium, and decreased renal tubular re-
absorption of calcium due to parathyroid suppression. In the
classic presentation (AH Type I), the syndrome is character-
ized biochemically by normocalcemia, normal or low serum
parathyroid hormone (PTH), high intestinal calcium absorption,
and hypercalciuria. Urinary calcium is high (>200 mg/day) on a
diet restricted in calcium (400 mg/day) and sodium (100
mEq/day), and remains high (>300 mg/day) on a high calcium
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diet. In normal subjects, it is <200 mg/day on a low calcium diet
and rarely exceeds 250 mg/day on a high calcium diet (4).
Fasting urinary calcium is normal, and is appropriate for the
level of parathyroid function. The intestinal hyperabsorption of
calcium is unaffected by reduction of urinary calcium by thi-
azide, or alteration of 1,25-dihydroxyvitamin D [1,25(OH)2D3]
synthesis or sensitivity by orthophosphate or steroid (5). 
AH may present itself in a less severe form (AH Type II),
wherein urinary calcium is normal on a calcium-restricted diet,
though elevated on a high calcium diet. It may also occur in a
severe form (fasting hypercalciuria), in which fasting urinary
calcium is high. Fasting hypercalciuria may reflect inadequate
duration of fast, incomplete renal clearance of absorbed calci-
um or reduced renal tubular reabsorption of calcium from sup-
pressed parathyroid function. In some patients, however, fast-
ing hypercalciuria may be reflective of concomitant bone loss.
Although radial shaft bone density is spared, spinal bone den-
sity has been reported to be reduced in AH type I and fasting
hypercalciuria (6). 
Potential Pathogenetic Role of Vitamin D
The pathogenetic role of vitamin D in AH is uncertain. Serum
1,25(OH)2D3 concentration has been reported to be either high
or inappropriately high. A biochemical-physiological picture of
AH can be produced by administration of 1,25(OH)2D3 to nor-
mal subjects. In some patients with AH, an inhibition of
1 , 2 5 ( O H )2D3 synthesis by a short-term treatment with keto-
conazole reduced intestinal calcium absorption and urinary cal-
cium (7). However, calcium absorption was shown to be in-
creased in the jejunum but not in the ileum or colon among pa-
tients with AH, whereas it was stimulated in all intestinal seg-
ments following treatment with 1,25(OH)2D3 (5).
In the genetic hypercalciuric rats stone-forming, 1,25(OH)2D3
receptors (VDR) in the intestine were two-fold higher than in
normocalciuric control rats (8), but VDR mRNA was not in-
creased (9). This increase in VDR was associated with a high-
er amount of calbindin-D9k. occurring primarily or secondary to
high VDR. Thus, in this animal model of AH, hypercalciuria
may be due to vitamin D-dependent stimulation of intestinal
calcium absorption. 
In human beings, no increase in VDR number or affinity for the
ligand for the receptor was found in monocytes and activated T
cells or in cultured skin fibroblasts from AH patients (10). There
was neither detectable mutations in the VDR coding sequence
nor an association of VDR polymorphisms with increased in-
testinal calcium absorption (11). Finally, linkage analysis failed
to implicate the VDR locus on chromosome 12 with the AH
phenotype (12). However, in another study, quantitative trait
analysis of urinary calcium excretion revealed linkage to some
but not all markers in the VDR region (13). The same study
eliminated the 1b-hydroxylase gene as being associated with
hypercalciuria. 
Genetic Studies in Human Beings with AH
AHRAC Gene. Prior studies have indicated that the inheritance
of AH is compatible with an autosomal dominant trait. Reed et
al. identified a locus on chromosome 1q23.3-24 in three kin-
dreds with phenotypically well-defined AH (12). Within this re-
gion, they identified a candidate gene, the absorptive hypercal-
ciuria-related adenylyl cyclase (AHRAC), on account of its as-
sociation with AH (14) and the cyclase function in the soluble
cytosolic cellular fraction described in its rat ortholog (15). The
gene is ubiquitously expressed in humans and a number of
base changes have been identified. While some of these base
substitutions in AHRAC can be found in the normal population,
the frequency in base changes was higher in patients with AH
(14). Figure 1 summarizes the allelic frequency of all the base
changes combined. Although one can easily find single base
changes in normal subjects, most patients with >4 base
changes have clinical AH.
Past studies have shown that A H R A C clearly encodes an
adenylyl cyclase and is expressed in the intestine. However, it
is not well understood at present how AHRAC regulates intesti-
al calcium transport and how the various polymorphic variants
lead to hyperabsorption of calcium. At the empirical level, the
intestinal absorption is positively correlated with the number of
base changes in A H R A C (Fig. 2). This finding strongly sug-
gests that AHRAC may control intestinal calcium absorption. It
is important to state that intestinal calcium absorption is a con-
tinuous variable under polygenic as well as non-genetic con-
trol. The elucidation of the function of wild type and variant
AHRAC in the gut should advance our knowledge of the patho-
physiology of AH.
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F i g u r e1 - Percentage of individuals harboring from 1-7 base changes in
AHRAC. Open bars depict normal volunteers (n = 155) and closed bars
indicate AH patients (n = 135).
F i g u r e2 - The relationship between calciuric response to oral calcium
load and number of base changes in AHRAC Phenotype. A 2-h fasting
urine collection was obtained for measurement of calcium and creati-
nine. After a synthetic meal containing 1 gm calcium, a 4-h urine collec-
tion was obtained for calcium and creatinine. The difference (D) be-
tween urinary calcium post-calcium load and fasting urinary calcium is a
surrogate of intestinal calcium absorption. N = number of subjects stud-
ied. Asterisk denotes statistically significant difference from subjects
with 1 base change (p<0.05 by ANOVA).
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Chloride channel. Dent’s disease (X-linked nephrolithiasis) is a
condition with hypercalciuria of yet unresolved pathogenesis
and “low molecular weight proteinuria” (urinary loss of proteins
of low molecular weight). Dent’s disease is caused by muta-
tions in the CLCN5 chloride channel. Although low molecular
weight proteinuria is highly prevalent in this disease, one indi-
vidual with documented CLCN5 mutation was found to have
hypercalciuria without proteinuria, raising the possibility that
CLCN5 mutations may underlie some patients with calcium
nephrolithiasis (16). Scheinman et al. found some degree of
low molecular weight proteinuria in 9% of patients with hyper-
calciuria but failed to show base changes in CLCN5 from geno-
tying 32 patients (16). Analysis of the genetic hypercalciuric
rats with stones also failed to show base changes in CLCN5. If
CLCN5 defects cause calcium nephrolithiasis outside the con-
text of Dent’s disease, the incidence is likely very low.
Sarcoidosis
Sarcoidosis is a granuloma-forming disorder characterized by
mild to severe hypercalcemia in 10% of patients, with hypercal-
ciuria occurring in up to 50% of patients at some time during the
course of their disease. For many years, it was believed that hy-
percalcemia and/or hypercalciuria resulted from increased sen-
sitivity to the biological effects of vitamin D. Subsequently, the
circulating concentrations of 1,25(OH)2D3 was found to be high,
due to its extrarenal synthesis by macrophages in sarcoid gran-
ulomata (17). Thus, the increased 1,25(OH)2D3 synthesis caus-
es hypercalcemia and hypercalciuria by stimulating intestinal
calcium absorption and stimulating bone resorption. 
The distinction between AH and sarcoidosis is best exemplified
by the glucocorticoid response. Glucocorticoids are effective in
the management of hypercalcemia of vitamin D toxicity and hy-
percalciuria associated with sarcoidosis and other granuloma-
tous conditions. Among patients with sarcoidosis, prednisolone
treatment significantly decreased serum 1,25(OH)2D3 and in-
testinal calcium absorption, whereas this treatment was uni-
formly ineffective among patients with AH (18). 
Pathophysiology of renal hypercalciuria (Table II)
Table II - Pathophysiology of Renal Hypercalciuria.
1. General Description
2. Physiological and Molecular Basis of Renal Hypercalciuria
a. Calcium Transport in the Nephron
b. Apical Calcium Channels
3. Regulators of Calcium Transport in the Nephron
a. Luminal pH
b. 1,25(OH)2D3 and Estrogen
c. Prostaglandin E2
d. Sodium Load
4. Clinical Conditions Associated with Renal Hypercalciuria
a. High Animal Protein Diet
b. Dietary Acid Load
c. PGE2 Excess
d. Dietary Sodium Load
e. Relative Hypoparathyroidism from Enhanced Intestinal Ca
Absorption
f. Estrogen Deficiency of Postmenopausal State
g. Mutations of ECaC Genes as a Potential Cause of Renal
Hypercalciuria
General Description
Renal hypercalciuria is an uncommon cause of hypercalciuric
nephrolithiasis. It is believed to result from a primary impair-
ment in the renal tubular reabsorption of calcium (5). The re-
sulting transient decline in serum calcium concentration stimu-
lates parathyroid function, which in turn enhances 1,25(OH)2D3
synthesis and intestinal calcium absorption. Biochemically,
serum calcium is normal and fasting urinary calcium is high co-
incident with elevated serum PTH, indicative of secondary hy-
rparathyroidism from renal calcium leak. A disturbed function
of renal proximal tubule was suggested by exaggerated calci-
uric response to carbohydrate ingestion, and accentuated natri-
uresis to thiazide challenge (19). Unlike in AH, the correction of
renal calcium leak by thiazide restores normal parathyroid
function and intestinal calcium absorption (5). 
Physiological and Molecular Basis of Renal Calcium Transport
Calcium Transport in the Nephron. The kidney is critical for
maintaining calcium homeostasis. To maintain calcium bal-
ance, about 98% of calcium load filtered by the glomerulus
must be reabsorbed along the nephron. Approximately 70-80%
of the filtered load of calcium is reabsorbed in the proximal
tubule and the thick ascending limb (TAL) of Henle’s loop. The
reabsorption of calcium in the proximal tubule and TAL occur
passively through the paracellular pathway. The remaining
about 20% of calcium reabsorption in kidney occurs via a tran-
scellular pathway in the distal part of the nephron, consisting of
distal convoluted tubules (DCT), connecting tubules and the
initial portion of the cortical collecting ducts. 
The transcellular reabsorption of calcium in the distal nephron
is a multi-step process (Fig. 3). It begins with passive entry of
Ca2+through Ca2+channels in the apical membranes, followed
by diffusion of Ca2+through cytosol facilitated by binding to the
1 , 2 5 ( O H )2D3-dependent Ca
2 +-binding protein (calbindin-D2 8 K) ,
and eventually by extrusion of Ca2+across the opposing baso-
lateral membranes. The extrusion of Ca2+across the basolater-
al membranes requires energy and is mediated by Na+/Ca2 +
exchangers and Ca2 +-ATPases operating against the electro-
chemical gradient for Ca2+. It has been postulated that the ini-
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F i g u r e3 - Renal calcium handling. Left panel: Relative absorptive rates
are shown as percentage of ultrafilterable calcium at the glomerulus.
Right panel: The scheme for transcellular transport of calcium in the
distal renal tubule. The apical entry step via ECaC1 is directly gated by
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tial passive entry through Ca2 + channels in the apical mem-
branes is likely the rate-limiting step of the trans-epithelial reab-
sorption of calcium in the distal nephron (20). 
Apical Calcium Channels. The cDNAs for the apical Ca2+chan-
nels in the distal nephron have been recently isolated. These
are called ECaC1 (for epithelial C a2 + channel-1) and ECaC2
(also known as TRPV5 and TRPV6 respectively). In the kidney,
TRPV5 and TRPV6 are localized to the apical membranes of
distal nephron (21). 
Regulators of Calcium Transport in the Nephron
Although the active transcellular reabsorption of calcium in the
distal nephron accounts for only about 20% of total reabsorbed
calcium, it is the major target for regulation by key factors impli-
cated in the development of hypercalciuria.
Luminal pH. Using patch-clamp electrophysiological recording
of recombinant EcaC1 channels expressed in cultured cells, low
extracellular pH directly inhibited ECaC1 channel activity with
an apparent pKa of 6.55 which is within the physiologic range of
luminal pH of the distal nephron (22). The direct inhibition oc-
curred as a result of extracellular proton titration of glutamate-
522 (rabbit ECaC1) in an extracellular loop. The ECaC1 activity
was inhibited by 16% for a drop in extracellular pH of 0.4. 
1,25(OH)2D3 and Estrogen. 1,25(OH)2D3 stimulates calcium re-
absorption via genomic mechanisms analogous to classical
steroid hormones. It increases the mRNA levels of both cal-
b i n d i n - D2 8 K and the Na
+/ C a2 + exchanger in a time frame that
requires a genomic mechanism (23). While not expressed as
high a level as calbindin-D28K, calbindin-D9K is also expressed
in the kidney and upregulated at the mRNA level by
1 , 2 5 ( O H )2D3. Recently, 1,25(OH)2D3 was shown to regulate
the expression of ECaC2 in the kidney (24). 1,25(OH)2D3 may
also influence calcium reabsorption by altering the expression
levels of the PTH receptor and 25-hydroxyvitamin D3- 2 4 - h y-
droxylase (23). 
Until recently estradiol has not been considered a calcitropic
hormone. However, recent studies in animal models of estro-
gen deficiency indicate that estrogens might have an effect on
calcium reabsorption in the kidney and calcium absorption in
the intestine independently of vitamin D. One model utilized
aromatase knockout (ArKO) mice. Aromatase synthesizes es-
trogens from androgen precursors. ArKO mice are deficient in
estrogens but not other gonadal factors. The ArKO female
mice had elevated urinary calcium/creatinine ratios despite
high serum PTH indicative of renal calcium leak (unpublished
observations, Öz et al.). Compared with the wild type mice, the
female ArKO mice had significantly lower expression of cal-
bindin-D28K, ECaC1, ECaC2, Na
+/Ca2+ exchanger and plasma
membrane Ca2 +pump, and lower protein levels of calbindin-
D28k, Na+/Ca2+exchanger, and plasma membrane Ca2+pump
in the kidneys (25,26). These data strongly support the possi-
bility that renal calcium leak is present in estrogen deficiency
through alteration in the expression or synthesis of molecules
involved in calcium transport in the distal nephron. 
The above role of estrogen is supported by other studies in ex-
perimental animals. Estradiol therapy in ovariectomized rats in-
creased the renal expression of calbindin-D28k without chang-
ing serum 1,25(OH)2D3 and ECaC1 mRNA (27). Moreover,
estradiol treatment of mice deficient in the 1a - ydroxylase or
VDR significantly increased ECaC1 mRNA, indicating a
1,25(OH)2D3-independent stimulatory effect of estradiol. 
Parathyroid Hormone. The mechanism by which PTH aug-
ments renal tubular reabsorption of calcium is not completely
understood. PTH is a potent inhibitor of proximal bicarbonate
reabsorption but causes minimal or modest bicarbonaturia
(28,29). Direct effect of PTH on the distal convoluted tubule
has been postulated but exactly how PTH increases calcium
transport in this segment is unknown (30). It is attractive to
speculate that the rise in luminal pH, due to the shift of bicar-
bonate reabsorption from the proximal to the distal nephron,
stimulates ECaC activity (22) and enhances reabsorption of
calcium. 
Prostaglandin E2 (PGE2). PGE2 has been shown to inhibit Ca
2+
transport in DCT (23). While the exact mechanism is unknown,
type-3 prostaglandin E2 (EP3) receptor may activate phospholi -
pase C, which may then decrease phosphatidylinositol 4,5-bis-
phosphate (PIP2) concentration in the membrane. It is possible
that the reduction in PIP2 by PGE2 can then decrease the ac-
tivity of ECaC1 directly or indirectly by enhancing the sensitivity
of ECaC1 to inhibition by acid. 
Sodium Load. As described above, the reabsorption of calcium
in the proximal tubule and TAL is passive and coupled to sodi-
um reabsorption (30). Sodium load and volume expansion in-
hibit reabsorption of sodium and calcium in these nephron seg-
ments and increase renal calcium excretion.
Clinical Conditions Associated with Renal Hypercalciuria
High Animal Protein Diet. A high animal protein diet has long
been known to cause hypercalciuria. Several mechanisms
have been invoked. It may partly be due to enhanced bone
loss (see Resorptive Hypercalciuria). Hypercalciuria of dietary
acid excess does not appear to be intestinal in origin since
there is no change in intestinal calcium absorption (31). High
dietary protein intake causes glomerular hyperfiltration, which
causes increased filtered load of calcium. The hypercalciuria,
however, is above and beyond that of an increased filtered
load to the kidney, indicating that a high dietary protein intake
also causes a direct inhibition of calcium reabsorption in the
kidneys (32). The possibility that hypercalciuria of animal pro-
tein excess is due to an acid-mediated renal calcium leak (33)
is supported by studies to be described below. 
Dietary Acid Load. On a daily basis, the normal Western diet
generates about 1 mEq/kg of acid in adult human beings. The
kidney is responsible for clearing the systemic acid load. How-
ever, there is a gradual reduction in overall renal function with
age, which reduces the ability of the kidneys to excrete acid
(34). When combined with a continued intake of animal pro-
teins (contain acid-generating components such as methionine
or cystine), a slight but significant acidemia may persist in the
elderly. Even in younger individuals, overindulgence of animal
proteins, can produce a degree of systemic acidity. The ensu-
ing metabolic acidosis or acid load can produce marked hyper-
calciuria. 
In a recent clinical study, a high protein-low carbohydrate
weight reducing diet increased net acid excretion by 54
mEq/day and reduced urinary pH by 0.5 unit (35). While urinary
calcium increased by 90 mg/day, intestinal calcium absorption
was not altered and changes in bone markers were unremark-
able. In another study, an animal model of animal protein ex-
cess was produced in rats by feeding a high casein diet (32).
Compared with a low casein diet, urinary calcium was 3-4 fold
greater on a high casein diet that was high in acid ash content.
In a preliminary study (unpublished observations, Preisig et
al.), the neutralization of the acid load by co-administration of
potassium citrate completely abrogated the rise in urinary calci-
um from the high casein diet. 
P G E2 Excess. It is known that high dietary protein intake in-
cr ases renal production of PGE2. In experimental animals, in-
16 Clinical Cases in Mineral and Bone Metabolism 2004; 1(1): 13-19
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tra-arterial administration of PGE2 increased urinary calcium
without changes in the systemic blood pressure or glomerular
filtration rate (36). Treatment with prostaglandin synthetase in-
hibitors restored normal urinary calcium among patients with
hypercalciuria. 
The complete abrogation of hypercalciuria of high animal pro-
tein diet by administration of alkali mentioned earlier suggests
that an increase in acid load is the principal factor for hypercal-
ciuria of high dietary protein intake. PGE2 may exacerbate hy-
percalciuria by increasing the sensitivity of ECaC1 to inhibition
by acid.
Dietary Sodium Load. A high dietary intake of sodium is well
known to increase urinary calcium by impairing renal tubular
reabsorption of calcium (37). An increment in dietary sodium of
100 mEq/day increases urinary calcium by about 40 mg/day.
While the slope is not altered, the intercept is higher in patients
with nephrolithiasis for each increment of sodium intake; thus,
there is higher degree of hypercalciuria (38). The induced hy-
percalciuria normally produces a compensatory rise in intesti-
nal calcium absorption, probably by stimulating parathyroid
function and the synthesis of 1,25(OH)2D3. 
Relative Hypoparathyroidism from Enhanced Intestinal Calcium
Absorption. In hypoparathyroidism, correction of hypocalcemia
by vitamin D often produces hypercalciuria. 
Estrogen Deficiency of Postmenopausal State. Several clinical
studies suggest that urinary calcium is increased in the post-
menopausal state, possibly due to estrogen lack. Among
women with stones, the urinary calcium significantly increased
during the 6th decade of life, coinciding with a rise in stone for-
mation rate (39). Compared with the untreated post-
menopausal women, those treated with estrogen had reduced
urinary calcium (fasting and 24-hour). The rise in urinary calci-
um following menopause appears to be renal in origin (40).
Sakhaee et al. reported on a group of postmenopausal women
with osteoporosis who displayed biochemical picture of renal
hypercalciuria with secondary hyperparathyroidism, associated
with high bone resorption on bone histomorphometric analysis
(40). Nordin et al. found that urinary calcium (corrected for cre-
atinine) was significantly greater in normal postmenopausal
women who had not received hormone replacement therapy,
compared with normal premenopausal women (41). The higher
urinary calcium in postmenopausal women could not be ex-
plained by increased filtered load of calcium. Lastly, McKane et
al. directly measured serum ultrafilterable calcium and tubular
reabsorption of calcium in early postmenopausal women be-
fore and following 6 months of estrogen therapy (42). After the
effect of changes in endogenous PTH secretion was excluded
by a pharmacologic dose of PTH, estrogen treatment signifi-
cantly increased the tubular reabsorption of calcium, providing
evidence that estrogen may directly lower urinary calcium inde-
pendently of PTH. Thus, the available clinical data suggest that
renal calcium leak is present in estrogen deficiency, and is cor-
rected by estrogen therapy. 
Mutations of ECaC Genes as a Potential Cause of Renal Hy -
percalciuria. As described above, ECaC1 and ECaC2 are criti-
cal gate-keepers of transcellular Ca2 + transport and primary
targets for regulation of renal calcium handling by calcitropic
hormones, dietary factors, and acid-base status. It is thus tan-
talizing to speculate that mutations of these genes may be re-
sponsible for genetic forms of renal hypercalciuria. In nine fam-
ilies with hypercalciuric nephrolithiasis, no mutations were
identified in the exons of ECaC. Haplotype analysis did not im-
plicate a role of the locus on chromosome 1. Single nucleotide
polymorphisms were noted in the 5’-flanking region. No geno-
type-phenotype association was identified (43). Since there is
likely loci heterogeneity, ECaC is not entirely ruled out as a
c ndidate gene for renal hypercalciuria. 
Pathophysiology of resorptive hypercalciuria (Table III)
T ble III - Pathophysiology of Resorptive Hypercalciuria.
1. Primary Hyperparathyroidism
2. Base Changes in AHRAC as a Part of AH Syndrome
3. Dietary Acid Load
In resorptive hypercalciuria, the primary defect responsible for
percalciuria is believed to be excessive bone resorption. The
prototype of resorptive hypercalciuria is primary hyperparathy-
roidism (PHPT) but it may also be seen in association with AH
and dietary animal protein excess. 
Primary Hyperparathyroidism
In PHPT, a hypersecretion of PTH from a benign solitary
parathyroid adenoma (80%) or multiglandular parathyroid hy-
perplasia (15%) produces excessive bone resorption. Under
normal circumstances, an increase in circulating ionized calci-
um is followed by a rapid decrease in PTH secretion. In PHPT
with adenoma, this feedback control is impaired, resulting in
hypersecretion of PTH. In PHPT caused by hyperplasia, the
sensitivity to circulating calcium is relatively intact but the num-
ber of parathyroid cells is increased, enhancing PTH secretion.
In either case, the PTH excess increases the number of active
osteoclasts on the bone surface, stimulating bone resorption.
The resulting rise in serum calcium increases the renal filtered
load of calcium, causing hypercalciuria. Although PTH aug-
ments renal tubular reabsorption of calcium, hypercalciuria en-
sues from the greatly increased filtered load of calcium and
from a suppressive effect of hypercalcemia on calcium reab-
sorption (44). 
PTH also induces the renal 25-hydroxyvitamin D3-1a -hydroxy-
lase; thus, serum 1,25(OH)2D3 concentration is often high in
PHPT. The enhanced 1,25(OH)2D3 synthesis stimulates osteo-
cl stic bone resorption and, more importantly, raises intestinal
calcium absorption. These effects further increase the circulat-
ing concentration of calcium and contribute to hypercalciuria.
Thus, hypercalciuria of PHPT is primarily resorptive and secon-
darily absorptive in origin. 
Base Changes in AHRAC as a Part of AH Syndrome
Despite intestinal hyperabsorption of calcium, patients with
AH tend to have negative calcium balance (45) and low spinal
bone mineral density (6). The most notable reduction in
spinal bone density was seen in patients with fasting hyper-
calciuria, implying a role for resorptive hypercalciuria (46).
The association between dietary risk factors (such as high
sodium and acid intake) and lower bone density is attenuated
in AH patients with the most severe fasting hypercalciuria,
suggesting presence of intrinsic bone defects in this sub-
group of AH patients (6). There is a 4-fold higher risk of frac-
tures in patients with hypercalciuria (47). Bone biopsies in pa-
ti nts with AH have shown a picture compatible with low bone
formation and turnover; less common are features suggestive
of increased bone resorption (48). In concert, these findings
Clinical Cases in Mineral and Bone Metabolism 2004; 1(1): 13-19 17
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provide compelling circumstantial evidence for bone involve-
ment in AH. 
At the molecular level, the number of base changes in AHRAC
has been shown to be well correlated well with reduced spinal
bone density in AH (14). Among AH patients with intestinal hy-
perabsorption of calcium, patients harboring A H R A C b a s e
changes had much lower bone density than those with wild
type A H R A C genotypes (14). While A H R A C is expressed in
bone, its current function in osteoblasts and osteoclasts are un-
known. It is conceivable that dysfunction of AHRAC can alter
the rate of bone formation that produces an inappropriately
high bone resorption in AH.
Dietary Acid Load
Besides impairing renal tubular reabsorption of calcium, meta-
bolic acidosis causes bone loss by physicochemical and cellu-
lar effects. When calvaria devoid of live bone cells are exposed
to an acid medium, calcium is released from dissolution of
bone mineral (calcium phosphate) (49). Calcium mobilization
from live calvaria is more marked due to stimulation of osteo-
clastic bone resorption and inhibition of osteoblastic bone for-
mation (50). 
In the previously cited animal model of animal protein excess
(32), we also evaluated the effect of chronic metabolic acidosis
on bone remodeling. On bone histomorphometric analysis, a
high casein diet with abundant acid ash content significantly in-
creased bone resorption and turnover (eroded surface, osteo-
clastic surface, mineralizing surface, and double layered tetra-
cycline surface), compared with a low casein diet (unpublished
observations, Zerwekh, Preisig et al.). Bone formation (os-
teoblast surface) was unaffected. Thus, there was a net bone
loss indicated by low bone volume, and reduced trabecular and
cortical thickness. In a preliminary study, the addition of potas-
sium alkali to the high casein diet returned above changes to-
ward the values of the low casein diet.  
Thus, dietary acid load produces high bone turnover and bone
loss, contributing to hypercalciuria. 
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